Your session is about to expire
← Back to Search
SGN-EGFRd2 for Advanced Cancer
Study Summary
This trial will test the safety & effectiveness of a drug, SGN-EGFRd2, in people with advanced solid tumors. It will also measure side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How does SGN-EGFRd2 compare in terms of safety when compared to similar treatments?
"Due to a lack of data related to its efficacy and safety, SGN-EGFRd2 has been assigned an initial score of 1."
Are there any openings currently available in this clinical research program?
"Clinicaltrials.gov displays that this clinical trial is currently accepting applicants, with the initial post-date being October 31st of 2023 and a subsequent update on October 24th of the same year."
What is the purport of this clinical trial?
"Per the clinical trial sponsor Seagen Inc., this study aims to quantify laboratory abnormalities over a 90 day period following completion of treatment. Secondary outcomes will be assessed with respect to pharmacokinetic parameters like Area under Curve, Maximum Concentration, and Time to Maximum Concentration; these metrics are summarily described through descriptive statistics."
To what extent is this scientific exploration being enacted by volunteers?
"Affirmative, clinicaltrials.gov lists this clinical trial as actively recruiting patients since its initial posting on October 31st 2023 and most recent update of October 24th 2022. This research requires 275 participants from a single medical site."
Share this study with friends
Copy Link
Messenger